#biopharmaceutical

Collection of biopharmaceutical news, found 131 news.

Aptorum Group announces significant progress of repurposed drug candidate, SACT-1 for neuroblastoma targeting IND submission in H2 2020

Aptorum Group announces significant progress of repurposed drug candidate, SACT-1 for neuroblastoma targeting IND submission in H2 2020

  • 11th February 2020

- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Aptorum Group announces further positive data for its ALS-4 small molecule Anti-virulence (Non-bactericidal) drug candidate for the treatment of infections caused by Staphylococcus aureus and on track

Aptorum Group announces further positive data for its ALS-4 small molecule Anti-virulence (Non-bactericidal) drug candidate for the treatment of infections caused by Staphylococcus aureus and on track

  • 10th February 2020

- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years

Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years

  • 23rd January 2020

- Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, ...

Takeda continues strategic divestitures with sale of select OTC and non-core assets to STADA for $660 million USD

Takeda continues strategic divestitures with sale of select OTC and non-core assets to STADA for $660 million USD

  • 5th November 2019

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an ...

Takeda agrees to divest select OTC and non-core assets to Acino for over $200 million USD

Takeda agrees to divest select OTC and non-core assets to Acino for over $200 million USD

  • 15th October 2019

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an ...

Hansoh Pharma and Atomwise launch strategic AI drug discovery collaboration for multiple therapeutic areas

Hansoh Pharma and Atomwise launch strategic AI drug discovery collaboration for multiple therapeutic areas

  • 13th September 2019

- Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and ...

APEC strives to bolster health ethics to support SMEs, patients

APEC strives to bolster health ethics to support SMEs, patients

  • 12th September 2019

APEC continues to bolster ethics in the healthcare sector in support of small and medium enterprises (SMEs) and ...

Aptorum Group has initiated IND-enabling studies for its ALS-4 small molecule candidate for the treatment of infections caused by staphylococcus aureus including MRSA

Aptorum Group has initiated IND-enabling studies for its ALS-4 small molecule candidate for the treatment of infections caused by staphylococcus aureus including MRSA

  • 9th September 2019

- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Aptorum Group announces the development of microbiome drug candidate targeting obesity and repurposed drug candidates targeting neuroblastoma

Aptorum Group announces the development of microbiome drug candidate targeting obesity and repurposed drug candidates targeting neuroblastoma

  • 9th September 2019

- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of ...

Takeda completes sale of Xiidra® to Novartis

Takeda completes sale of Xiidra® to Novartis

  • 2nd July 2019

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale ...

Terns Pharmaceuticals appoints Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer

Terns Pharmaceuticals appoints Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer

  • 1st July 2019

- Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative ...

Terns Pharmaceuticals announces exclusive licensing and collaboration agreement with GENFIT to develop and commercialize elafibranor in the Greater China region

Terns Pharmaceuticals announces exclusive licensing and collaboration agreement with GENFIT to develop and commercialize elafibranor in the Greater China region

  • 25th June 2019

- Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a ...

Aeneas Capital and Pyrinas target launch of US$120m fund to develop co-working laboratory ecosystems for life sciences start-ups in the United States

Aeneas Capital and Pyrinas target launch of US$120m fund to develop co-working laboratory ecosystems for life sciences start-ups in the United States

  • 16th May 2019

    • Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group Ltd (Nasdaq: APM), is ...

Takeda simplifies portfolio and accelerates deleveraging through two divestitures

Takeda simplifies portfolio and accelerates deleveraging through two divestitures

  • 9th May 2019

- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into ...

Terns Pharmaceuticals to present at BioCentury’s 26th Annual Future Leaders in Biotech Industry Conference

Terns Pharmaceuticals to present at BioCentury’s 26th Annual Future Leaders in Biotech Industry Conference

  • 8th April 2019

- Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly ...